drugset / Trial / NCT04582864
Flotetuzumab for Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation (Allo-HCT)
Phase 2
Terminated
11 enrolled
Washington University School of Medicine
MacroGenics · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The investigators hypothesize that flotetuzumab for relapsed AML following allo-HCT will be safe, tolerable and may facilitate preferential immune effector cell retargeting of leukemic cells resulting in improved patient outcomes. Furthermore, administration of a donor lymphocyte infusion (DLI) (if available) in combination with flotetuzumab will be safe, tolerable and may provide additional therapeutic efficacy.
Timeline
- Start
- 2021-05-20
- Primary completion
- 2024-03-29
- Completion
- 2024-07-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Flotetuzumab | Monoclonal antibody | 0.5 ug/kg | Intravenous |